Analystreport

Can-Fite BioPharma (NYSE:CANF) was upgraded by analysts at Zacks Research to a "hold" rating.

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com